{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:10:12Z","timestamp":1779433812609,"version":"3.53.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Jiangxi Province Key Research and Development Plan Project","award":["20202BBGL73038"],"award-info":[{"award-number":["20202BBGL73038"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"abstract":"<jats:p>This study aims to compare the effectiveness and safety of anti-programmed cell death protein 1 (PD-1) immunotherapy and tyrosine kinase inhibitors (TKIs) combined with intra-arterial therapy (IAT) or systemic chemotherapy, and anti-PD-1 immunotherapy combined with IAT or systemic chemotherapy in patients with advanced biliary tract carcinoma (BTC). Patients with BTC who received IAT combined with anti-PD-1 immunotherapy and\/or TKIs or the combination of systemic chemotherapy with anti-PD-1 immunotherapy and\/or TKIs were divided into 4 groups according to inclusion and exclusion criteria: the combination of IAT with TKIs and anti-PD-1 immunotherapy group (ITP group), the systemic chemotherapy combined with TKIs and anti-PD-1 immunotherapy group (CTP group), the combination of IAT with anti-PD-1 immunotherapy group (IP group) and the systemic chemotherapy combined with anti-PD-1 immunotherapy group (CP group). The baseline characteristics, progression-free survival (PFS), treatment efficacy and adverse reactions were compared between ITP and CTP groups and between IP and CP groups, and risk factors related to PFS were analyzed. The median PFS in ITP group was 3.975 months, and the 6-month-PFS was 31.6%; the median PFS in CTP group was 3.285 months, and the 6-month-PFS was 11.1%. There was a statistical difference between ITP group and CTP group. The median PFS in the IP and CP groups were 4.534 months and 2.267 months, respectively, which were also statistically significant. The objective response rate and disease control rate (DCR) of ITP and CTP groups were not statistically significant. There was no significant difference in objective response rate and DCR between IP group and CP group. The lymph node metastasis was an independent risk factor for PFS. Compared with the CTP group, the ITP group had a higher incidence of post-treatment fever and difficulty urination, and the IP group had a higher incidence of 3\u2009degree AST elevation and difficulty urination than the CP group. IAT combined with anti-PD-1 immunotherapy and TKIs or IAT combined with anti-PD-1 immunotherapy for advanced BTC were relatively effective and safe. The lymph node metastasis was an independent risk factor affecting the prognosis of advanced BTC.<\/jats:p>","DOI":"10.1097\/md.0000000000046213","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T04:00:53Z","timestamp":1766203253000},"page":"e46213","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Intra-arterial therapy combined with immunotherapy and\/or targeted therapy for advanced biliary tract carcinoma: A retrospective study"],"prefix":"10.1097","volume":"104","author":[{"given":"Mengjie","family":"Li","sequence":"first","affiliation":[{"name":"Graduate School, The First Clinical Medical College of Nanchang University, Nanchang, Jiangxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqiang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Graduate School, The First Clinical Medical College of Nanchang University, Nanchang, Jiangxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhan","sequence":"additional","affiliation":[{"name":"Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxing","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"He","sequence":"additional","affiliation":[{"name":"Department of oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1919-2862","authenticated-orcid":false,"given":"Yuling","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260522","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management.","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20260522","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20260522","first-page":"99","article-title":"Gallbladder cancer: epidemiology and outcome.","volume":"6","author":"Hundal","year":"2014","journal-title":"Clin Epidemiol"},{"key":"R4-20260522","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma.","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"R5-20260522","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1200\/JCO.21.02576","article-title":"Precision medicine in biliary tract cancer.","volume":"40","author":"Scott","year":"2022","journal-title":"J Clin Oncol"},{"key":"R6-20260522","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"R7-20260522","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R8-20260522","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S2468-1253(24)00118-3","article-title":"Immunotherapy in biliary tract cancer: are we finally on the right path?","volume":"9","author":"Ricci","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R9-20260522","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3390\/cancers16101835","article-title":"Prognostic significance of the royal marsden hospital (RMH) score in patients with cancer: a systematic review and meta-analysis.","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R10-20260522","first-page":"624","article-title":"Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data.","volume":"31","author":"Guven","year":"2023","journal-title":"Support Care Cancer"},{"key":"R11-20260522","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"R12-20260522","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3390\/cancers12051237","article-title":"Biliary tract cancer: current medical treatment strategies.","volume":"12","author":"Oneda","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R13-20260522","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/hbsn.2016.11.02","article-title":"Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects.","volume":"6","author":"Savic","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R14-20260522","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/1751-2980.13127","article-title":"Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.","volume":"23","author":"Zhang","year":"2022","journal-title":"J Dig Dis"},{"key":"R15-20260522","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29824","article-title":"Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.","volume":"122","author":"Konstantinidis","year":"2016","journal-title":"Cancer"},{"key":"R16-20260522","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5582\/bst.2017.01320","article-title":"Arterial infusion of cisplatin plus S-1 against unresectable intrahepatic cholangiocarcinoma.","volume":"12","author":"Higaki","year":"2018","journal-title":"Biosci Trends"},{"key":"R17-20260522","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial.","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol"},{"key":"R18-20260522","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.21873\/anticanres.11522","article-title":"Chemoembolization with drug-eluting microspheres loaded with doxorubicin for the treatment of cholangiocarcinoma.","volume":"37","author":"Aliberti","year":"2017","journal-title":"Anticancer Res"},{"key":"R19-20260522","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"R20-20260522","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","article-title":"Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.","volume":"4","author":"Ueno","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R21-20260522","doi-asserted-by":"crossref","first-page":"618206","DOI":"10.3389\/fonc.2021.618206","article-title":"Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma.","volume":"11","author":"Mei","year":"2021","journal-title":"Front Oncol"},{"key":"R22-20260522","doi-asserted-by":"crossref","first-page":"17588359211002720","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma.","volume":"13","author":"He","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"R23-20260522","first-page":"3455","article-title":"Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer: a multicenter retrospective study.","volume":"12","author":"Zhang","year":"2022","journal-title":"Am J Cancer Res"},{"key":"R24-20260522","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1148\/radiol.2016160572","article-title":"Phase II study of hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced perihilar cholangiocarcinoma.","volume":"283","author":"Wang","year":"2017","journal-title":"Radiology"},{"key":"R25-20260522","first-page":"9680933","article-title":"The efficacy and safety of hepatic arterial infusion chemotherapy based on FOLFIRI for advanced intrahepatic cholangiocarcinoma as second-line and successive treatment: a real-world study.","volume":"2022","author":"Huang","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R26-20260522","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R28-20260522","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/hep.30289","article-title":"Intrahepatic cholangiocarcinoma: continuing challenges and translational advances.","volume":"69","author":"Sirica","year":"2019","journal-title":"Hepatology"},{"key":"R29-20260522","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4254\/wjh.v12.i10.693","article-title":"Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma.","volume":"12","author":"Akateh","year":"2020","journal-title":"World J Hepatol"},{"key":"R30-20260522","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"R31-20260522","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study.","volume":"109","author":"Yuan","year":"2023","journal-title":"Int J Surg"},{"key":"R32-20260522","doi-asserted-by":"crossref","first-page":"e0266707","DOI":"10.1371\/journal.pone.0266707","article-title":"Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.","volume":"17","author":"Ishii","year":"2022","journal-title":"PLoS One"},{"key":"R33-20260522","doi-asserted-by":"crossref","first-page":"611118","DOI":"10.3389\/fonc.2021.611118","article-title":"Survival comparisons of hepatic arterial infusion chemotherapy with mFOLFOX and transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma.","volume":"11","author":"Cai","year":"2021","journal-title":"Front Oncol"},{"key":"R34-20260522","doi-asserted-by":"crossref","first-page":"102258","DOI":"10.1016\/j.ctrv.2021.102258","article-title":"Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis.","volume":"99","author":"Edeline","year":"2021","journal-title":"Cancer Treat Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:01:30Z","timestamp":1779433290000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":33,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046213","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"2025-07-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}